Home
NewsNewsMalaysia's government targets 30,000 couples with subsidised fertility treatment assistance through the BUAI programme to address the nation's declining birth rate.
Malaysia's government has launched an ambitious initiative targeting 30,000 couples nationwide to benefit from subsidised fertility treatment assistance, addressing the country's declining birth rate which has reached its lowest level since 1980. The programme, managed by the National Population and Family Development Board (LPPKN), aims to increase the birth rate through strategic healthcare interventions and family support mechanisms.
Deputy Women, Family and Community Development Minister Datuk Seri Dr Noraini Ahmad unveiled the initiative during the Institut Sosial Malaysia Executive Talk Programme at Al-Sultan Abdullah Hospital, Universiti Teknologi Mara (UiTM) Puncak Alam on October 22. The fertility treatment assistance programme, formally known as the Fertility Treatment Assistance and Infertility Advocacy Programme (BUAI), represents a comprehensive approach to supporting couples facing conception challenges.
"Through strategic collaboration between LPPKN and selected hospitals, couples facing challenges in conceiving will be assisted, particularly those who meet the eligibility criteria, such as for their first childbirth," Dr Noraini explained. The fertility treatment assistance initiative covers intrauterine insemination (IUI) procedures and provides advocacy support specifically designed to address Malaysia's declining fertility issue.
The government's commitment extends beyond clinical intervention. The ministry has introduced complementary programmes including the Family Education Programme (PEKERTI Smart Start) and the Reproductive and Family Health Education Club (KPTI) to expose university students to reproductive health knowledge and family values. Through KPTI, university students become volunteers and peer educators, sharing critical knowledge about reproductive health with their peers.
Malaysia faces significant demographic transformation challenges. According to the Vital Statistics Malaysia 2025 released by the Department of Statistics Malaysia (DOSM), the nation recorded 414,918 live births in 2024, a nine per cent decline from 455,761 in 2023, marking the lowest birth rate since 1980. This demographic shift necessitates urgent policy interventions.
Dr Noraini emphasised that the fertility treatment assistance initiative aligns with the government's commitment to strengthening family institutions while supporting national population sustainability. "Reproductive health and family policies must remain a core priority for the nation in addressing major challenges involving the health system, social networks and economic resilience," she stated.
The BUAI programme's implementation through strategic partnerships with hospitals ensures accessibility across the nation. By combining clinical fertility treatments with educational initiatives, Malaysia's government demonstrates a multifaceted approach to reversing fertility decline while promoting informed family planning decisions.
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
